NEWS

NEWS

Two new publications out

We contributed to a paper on a newly generated reporter line expressing NanoLuciferase. Within two weeks another paper we collaborated on came out about blocking transmission of gametocytes. Read more ...
/ News

Collaboration leads to breakthrough insights in olfactory representation

In a collaboration with Google Research and Osmo, TropIQ contributed to a landmark paper that provides fundamental insights into the relationship between odors. It demonstrates that perceptual similarity is related ...
/ News

Miniaturized sporozoite assays identify antimalarials acting on liver schizogony

We investigated how susceptible the early stages of malaria are to chemical treatments, and we created a screening strategy to identify new drugs that can prevent infection. The results are published in ...
/ News

New transmission-blocking antibodies found

TropIQ contributed to two studies that identified novel malaria transmission-blocking monoclonal antibodies from naturally exposed individuals. These studies are published in Immunity. Read more here and here ...
/ News

TropIQ contributes to arresting growth late in the liver

TropIQ assessed drug sensitivity of a new genetically attenuated malaria parasite that qualifies as a vaccine candidate. The results of these studies have been now been published in NPJ Vaccines ...
/ News

Digital olfaction predicts mosquito behaviour

From our collaborative work with computational scientists at Google Brain, two exciting preprints have been released on BioRxiv. The first describes an accurate model for odor perception that holds true ...

TropIQ presents at the Drug Design and Development seminar in Munich

TropIQ will contribute two oral presentations to the 2022 Drug Design and Development Seminar of the German Society for Parasitology: Analysis of tick regurgitation following mechanical, cryogenic and chemical removal ...
/ News

MMV, PPSC and TropIQ present a webinar on state of the art in malaria phenotypic screening

On June 22nd at 4 pm CET, the Medicines for Malaria Venture, the Pivot Park Screening Centre and TropIQ will present a webinar on their collaborative work in malaria phenotypic ...
/ News

Antimalarial MMV’183 is a clinical development candidate

TropIQ's parasitology platform drove the optimisation of pantothenamide compounds that generated MMV'183: a candidate for further clinical development with a new mode of action for treatment of malaria and blocking transmission ...
/ News

TropIQ publishes innovative mosquito barcoding technology

We present a barcoding strategy that enables phenotypic screens of blood-feeding insects against small molecules in microtiter plate-based arrays and apply this to discovery of novel systemic insecticides and compounds ...
/ News

TropIQ awarded large research grant to uncover new mosquito repellents.

Together with researchers from the University of Washington, TropIQ was awarded 1.3 million USD from the Bill & Melinda Gates Foundation to find new mosquito repellents and thus aid the ...
/ News

MalDA prioritises malaria drug targets with TropIQ’s input

The Malaria Drug Accelerator (MalDA), of which TropIQ is part of, has put together a prioritisation of molecular targets against the malaria parasite Plasmodium falciparum. This publication further advocates target ...
/ News

Our team aids the discovery of a new anti-malarial scaffold.

Due to the continuing rise of resistances against commonly used medication, new anit-malarials are needed to combat the disease. This publication suggests Quinazolinone-2-carboxamide derivatives as a novel malaria drug. read ...
/ News

Review of MalDA’s scientific achievements just released

TropQI has been a part of The Malaria Drug Accelerator (MalDA) since 2018. This consortium consists of 17 research laboratories funded by the Bill and Melinda Gates foundation to advance ...
/ News

Our liver stage platform supports life cycle profiling for new anti-malarial.

In the battle against malaria new drugs are needed. This publication identified 1-(pyridine-4-yl)pyrrolidine-2-one derivates as a novel, dual stage active (asexual blood stages and liver stage), anti-malaria. read more here ...
/ News

TropIQ assists in life cycle profiling of genetically modified chimeric Plasmodium parasite.

To broaden the protective spectrum of a potential whole parasite vaccine against malaria, a chimeric P. falciparum parasite expressing P. falciparum and P. vivax circumsporozoite protein (csp) was generated. This ...
/ News

TropIQ Digitalises Its Discovery Platform with CDD Vault

CDD Vault will enable TropIQ Health Sciences to share research results with partners in real time Nijmegen and San Francisco October 8, 2020 TropIQ Health Sciences, a  biotechnology ...
/ News

TropIQ contributes to research on malaria vaccine

Production of the primary vaccine candidate Plasmodium falciparum circumsporozoite protein (PfCSP) has proven difficult. This publication for the first time presents a method to produce a soluble, full-length PfCSP which ...
/ News

Dr. Sheshachalam is joining TropIQ

Dr. Sheshachalam has joined the team as a Scientist. He is an experienced cell biologist with a broad expertise in immunology, molecular biology and drug discovery. He obtained his PhD ...
/ News

TropIQ CEO Koen Dechering gives radio interview on the new malaria drug candidate

Dutch national radio (BNR) has conducted an interview with TropIQ's CEO Koen Dechering on the recently published novel malaria drug candidate (see publication here). Listen to the interview here (in ...
/ News